TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Xspray Pharma AB ( (SE:XSPRAY) ).
At the recent annual general meeting, Xspray Pharma AB resolved to adopt the financial statements for 2024, re-elected board members, and introduced a long-term incentive program for employees. The company also authorized the board to issue new shares and warrants, potentially impacting shareholder rights and company growth strategies.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company specializing in the development of improved protein kinase inhibitors (PKIs) for cancer treatment. Utilizing its proprietary HyNap™ technology platform, the company focuses on enhancing the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are publicly traded on Nasdaq Stockholm.
Average Trading Volume: 20,007
Current Market Cap: SEK1.03B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.